Coccidiosis is a widespread disease
caused by a single cell parasite that can be seen only with the help of a
microscope. Every livestock species as well as wild animals can be
infected by coccidiosis, which is particularly prevalent when animals or
birds are grouped together in significant numbers. The disease results
in lower egg production in chickens and is responsible for mortality in
the flock. Commonly, three to four species of coccidian are responsible
for the outbreak of the disease. The severity of the disease depends on
the number of oocyte ingested and on the species of coccidia.
Anticoccidial drugs are those entities that combat the progression of
coccidiosis in animals or birds. Anticoccidials are administered in the
feed to prevent disease and minimize the economic loss often associated
with sub-acute infections. Prophylactic use of anticoccidial drugs is
preferred many a times as most of the damage occurs before clinical
signs become apparent.
The anticoccidial drugs market can be
segmented based on action, drug entity, and region. In terms of action,
the anticoccidial drugs market can be classified into coccidiostatic and
coccidiocidal. Based on drug entity, the anticoccidial drugs market can
be categorized into ionophores and synthetic anticoccidials. The
ionophores segment can be further divided into monovalent, monovalent
glycoside, and divalent. Ionophores are the fermentation products of
fungi species. They are extensively used as anticoccidial agents.
Salinomycin, lasalocid, and monensin are the most commonly used
ionophores. In terms of geography, the anticoccidial drugs market can be
segmented into North America, Europe, Asia Pacific, Latin America, and
Middle East & Africa.
North America accounts for a significant
anticoccidial drugs market share in terms of revenue, due to a
well-established infrastructure in immunological research, highly
organized farming, increased demand for animal protein, high pet
ownership, greater emphasis on prevention and wellness by veterinarians,
and rise in spending on medicine. According to the USDA Economic
Research Service, poultry is the fastest growing meat product in the
organic products anticoccidial drugs market in the U.S.. The size of the
poultry segment is around US$ 56 Mn. The segment expanded at an annual
growth of 33% through 2008 (USDA, 2008). The high consumption of meat is
expected to propel the anticoccidial drugs market in North America.
Europe is a prominent region of the anticoccidial drugs market, owing to
a highly developed health care industry, high government funding for
the development of veterinary medicines, increased awareness among
people, and high consumption of meat. The Biotechnology and Biological
Sciences Research Council (BBSRC) donated GBP 5.7 Mn for the development
of poultry vaccines to the London School of Hygiene and Tropical
Medicine in December 2015.
The anticoccidial drugs market in Asia
Pacific is expanding at a robust pace due to high rate of development in
veterinary medicines and increase in government initiatives. Nowadays,
major pharmaceutical companies are outsourcing their drug development
services to various countries such as China, Singapore, Malaysia, and
India, which is eventually propelling the growth of the anticoccidial
drugs market in this region. The global anticoccidial drugs market is
witnessing considerable growth owing to a rise in disposable income of
people in emerging countries. Disposable income is increasing in
emerging countries such as India and China, which results in a change in
lifestyle and high demand for animal protein foods such as meat, milk,
etc.. Increase in disposable income is likely to boost demand for
veterinary pharmacies. Middle East and Latin America are expected to be
the prospective regions of the anticoccidial drugs market in the near
future due to rapidly developing pharmaceutical and biotechnology
industries.
Some of the major players operating in
the anticoccidial drugs market are Bayer Animal Heath, Boehringer
Ingelheim, Ceva Santé Animale, Elanco, Novartis Animal Health, Merck
Animal Health, Merial, Virbac S.A., and Zoetis.
No comments:
Post a Comment